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ABSTRACT
Purpose
Symptom clusters (SCs) are a dynamic construct. They
consist of at least 2 or 3 interrelated symptoms that
may be a significant predictor of patient morbidity. In
a previous study, we identified 2 SCs in patients with
bone metastases:
• An activity-related interference cluster
￿ A psychology-related interference cluster
These SCs may be clinically important in the pain
and symptom management of patients with metastatic
bone pain. It is therefore important to validate the re-
ported SCs to determine if they hold true across similar
patient populations.
Patients and Methods
From February to September 2007, our study accrued
52 patients with bone metastases [29 men (56%), 23
women (44%); median age: 68.5 years (range: 39–87
years)] who were referred for palliative radiotherapy
(RT). Prostate (31%), breast (29%), and lung (19%)
were the most common primary cancer sites. Treat-
ment arms ranged from single to multiple fractions,
with most patients receiving a single 8-Gy fraction
(77%) or 20 Gy in 5 fractions (21%). The most preva-
lent sites for RT were spine (42%), hips (17%), and
pelvis (14%). Worst pain at the site of RT and func-
tional interference scores were assessed using the
Brief Pain Inventory (BPI), a multidimensional pain
instrument that uses 11-point numeric rating scales.
Patients provided their symptom severity scores on
the BPI at baseline and at 4, 8, and 12 weeks post RT.
At all time points, a principal component analysis with
varimax rotation was performed on 8 items (worst
pain and 7 functional interference items) to determine
relationships between symptoms before and after RT
for bone pain.
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Results
Two SCs were identified. Cluster 1 included worst pain
and interference with general activity, normal work,
and walking ability; cluster 2 consisted of interference
with mood, sleep, enjoyment of life, and relations with
others. Our statistical analysis produced varied results
for the 2 clusters found in our previous investigation.
These differences may be an indicator for the instabil-
ity of SCs or may be a result of the fewer number of
patients accrued in the present validation study.
Conclusions
The SCs in our two studies were not identical for pa-
tients receiving palliative RT for symptomatic bone
metastases. Another SC validation study should be con-
ducted with a larger sample before a conclusion is
drawn about the existence of an unstable phenomenon
in SC research.
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1. INTRODUCTION
Bone metastasis is a frequent complication of cancer
and has been found in 70%–85% of cancer patients at
autopsy 1. Metastasis most often occurs in patients with
primary breast, prostate, and lung tumours 2. Approxi-
mately 50%–75% of patients will require treatment for
their metastatic bone pain with the aim of symptom
palliation 3. Radiation therapy has been shown to re-
lieve bone pain in approximately 80% of patients 4.
The Brief Pain Inventory (BPI) is a multidimen-
sional instrument that was originally developed in 1994
by Cleeland and Ryan 5 to address the problem of inad-
equate pain control in cancer patients. The BPI is the
most frequently used multiple-item measure of pain in
cancer research 6, and it is measured on the sensory
and affective dimensions. The sensory component ofVALIDATION OF SYMPTOM CLUSTERS
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pain intensity measures worst, average, and current pain,
and the affective dimension of functional interference
includes general activity, normal work (including work
outside the home and housework), walking ability, mood,
sleep, relations with others, and enjoyment of life. Pre-
vious research found that changes in worst pain are sig-
nificantly correlated with 6 of the 7 life functions,
“relations with others” being the exception 7,8.
The term “symptom cluster” was first coined by
Dodd, Miaskowski, and Paul in 2001 in their work with
pain, fatigue, and sleep disturbances 9. Symptom clus-
ters have been proposed to consist of at least 2 10 or 3 9
interrelated symptoms in a stable group that is relatively
independent of other clusters and that possibly reveals
specific underlying dimensions or mechanisms 10.
Symptoms within a cluster may or may not have the
same underlying cause 9. However, to be considered
clustered, symptoms must have a stronger relationship
with symptoms in the same cluster than with symp-
toms in other clusters 10. Because the BPI assesses pain
on several dimensions, the present study defined a
symptom cluster as 2 or more interrelated symptoms
or functional interference items.
From May 2003 to January 2007, we conducted a
previous study at the Odette Cancer Centre and, using
the BPI, extracted 2 symptom clusters in patients re-
ceiving palliative radiation therapy (RT) for sympto-
matic bone pain 11. The 348 individuals who agreed to
participate in the study completed the BPI before RT
(baseline) and at weeks 4, 8, and 12 post RT 11.
Two symptom clusters were identified at baseline:
￿ An activity-related interference cluster (cluster 1)
￿ A psychological-related interference cluster (cluster 2)
Cluster 1 consisted of worst pain and interference
with normal work, general activity, walking ability, and
enjoyment of life. Cluster 2 consisted of interference
with relations with others, sleep, and mood. In respond-
ers to RT, no symptom clusters were identified in the
follow-up assessments. However, in non-responders to
radiation, symptom clusters appeared at week 8 post
RT. Symptom clusters appear to be unstable, and so it
is clinically important to validate reported symptom
clusters found in previous research to determine if they
hold true across similar patient populations.
The primary objective of the present study was to
validate the findings from our previous study 11 by com-
paring the extracted symptom clusters at baseline and
at 4, 8, and 12 weeks post RT.
2. PATIENTS AND METHODS
The Rapid Response Radiotherapy Program (RRRP) at
the Odette Cancer Centre is an innovative program that
was initiated in 1996 to provide timely palliative RT for
symptom relief in patients with advanced disease 12.
The RRRP provides an opportunity for cancer patients
to be assessed, planned, and treated on the day of first
consultation so as to relieve symptomatic cancer pain
and to maintain or improve quality of life.
All patients referred to the RRRP for palliative RT
of symptomatic bone metastases were considered for
this study. For study participation, patients had to be at
least 18 years of age, to have radiologic evidence of
bone metastases, and to provide informed consent. Pa-
tients were excluded if there was a language barrier or
if they had experienced a pathologic fracture or spinal
cord compression.
From February to September 2007, 52 patients from
the RRRP were enrolled into the study. At initial con-
sultation, patients with bone metastases were asked to
rate their worst pain and functional interference scores
on the BPI using 11-point numeric rating scales. The
numeric rating scales had descriptive anchors of 0 for
“no pain” or “does not interfere” and 10 for “worst
imaginable pain” or “completely interferes.”
All reference to pain was specific to the irradi-
ated site in these patients. Patient demographics, which
included age, sex, cancer history, Karnofsky perform-
ance status (KPS) 13, and analgesic consumption dur-
ing the preceding 24 hours were recorded at the first
visit. Opioid analgesics were converted to total daily
oral morphine equivalent doses. The progress of a pa-
tient’s response to palliative RT was monitored using
the BPI at 4, 8, and 12 weeks post RT. A research as-
sistant was responsible for obtaining BPI scores in tel-
ephone interviews.
Patient confidentiality was maintained, and patients
were assigned a unique number for study identifica-
tion purposes. Ethical approval was obtained from the
hospital research ethics board, and all questionnaire
administration and information collection was per-
formed by a trained research assistant. The entire proc-
ess was consistent with the principles set out in the
Declaration of Helsinki on conducting clinical research.
Our study defined responders to radiation treatment
as patients experiencing a complete (CR) or partial re-
sponse (PR). The International Bone Metastases Con-
sensus Working Party 14 defines “complete response”
as a pain score of 0 at the irradiated site, with no con-
comitant increase in analgesic intake (stable or reduced
analgesics in daily oral morphine equivalent doses). It
defines “partial response” as a pain reduction of 2 points
or more at the irradiated site on a 0–10 scale without
analgesic increase or with an analgesic reduction of 25%
or more from baseline without an increase in pain 14.
2.1 Statistical Analyses
Results are expressed as mean ± standard deviation or
median and range for quantitative variables, and as
proportions for categorical findings. The chi-square test
was used to test for differences in the averages of symp-
tom severity and of functional interference scores be-
tween the sexes. The Spearman correlation was applied
at baseline to determine the strength of the correlation
between any 2 of the 8 items.HADI et al.
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Principal component analysis (PCA) with varimax
rotation was applied to worst pain and the 7 functional
interference items. To determine relationships between
items before and after RT for bone pain, PCA was per-
formed on the 8 items at each time point for respond-
ers and for non-responders alike.
The highest factor loading score predicted the as-
signment of individual symptoms to an independent
factor. The Cronbach alpha statistic was used to esti-
mate the internal consistency and reliability of the
derived clusters at baseline and at subsequent follow-
ups. Using a biplot graphic, robust relationships and
correlations between the 8 items were displayed; the
length and proximity of arrows acted as determinants
of the strength of the correlations. The final
communality refers to the percentage variance in an
observed variable that was accounted for by the re-
tained clusters.
A general linear mixed model was used to deter-
mine whether the BPI items changed over time (from
baseline to week 12) in all patients and whether a re-
sponder effect occurred over time (from week 4 to week
12). Results were considered significant at the 5% criti-
cal level (p < 0.05). All calculations were performed
using the SAS (version 9.1: SAS Institute, Cary, NC,
U.S.A.) and S-PLUS (version 7.0: Mathsoft, Cambridge,
MA, U.S.A.) statistical software packages.
3. RESULTS
From February to September 2007, our study accrued
52 patients with symptomatic bone metastases [29 men
(55.8%), 23 women (44.2%); median age: 68.5 years
(range: 39–87 years)] who received RT. All participants
provided complete baseline data at initial consultation.
Table I summarizes patient demographics and disease
information. These patients had a median KPS of 70
(range: 40–90) and a median daily morphine equiva-
lent dose of 10 mg. Prostate (30.8%), breast (28.9%),
and lung (19.2%) were the most common primary can-
cer sites. Most patients received a single fraction of 8
Gy to the spine.
Table II lists the prevalences, sex differences, and
median severities for “worst pain” and the 7 functional
interference items. A symptom was considered present
if it was scored greater than 0. All 52 patients had a
“worst pain” score.
The 3 most prevalent interference items were gen-
eral activity (88.2%), enjoyment of life (88.0%), and
normal work (85.7%). For individuals who were expe-
riencing interference, all 8 items had a moderate-to-
severe functional median severity score, with normal
work being the highest (median score: 8). In using chi-
square analyses to test for sex differences, we observed
no significant difference between women and men on
any BPI item except for relations with others (p = 0.029).
Before RT, some of the patients did not experience
certain functional interference items. For those who
provided a score, Table III lists the symptom distress
of patient-assessed worst pain and of functional
interference scores. The median symptom distress
ranged from 3.5 to 7 for the 8 items. “Worst pain” and
“normal work” had the highest symptom distress, with
“relations with others” ranking lowest.
The Spearman correlations in Table IV depict the
strength of the relationships between the 8 items. Each
Spearman correlation was highly significant (p <
0.0001), except for the relationships of sleep with pain
(p = 0.0008), with general activity (p = 0.0004), with
walking ability (p = 0.0068), and with relations with
others (p = 0.0029). Other nonsignificant Spearman
correlations were observed for enjoyment of life with
walking ability (p = 0.0014) and with normal work (p =
0.0003), and for relations with others with normal work
(p = 0.0015). Correlations between items ranged from
0.38 to 0.88, with the lowest correlation occurring be-
tween sleep and walking ability, and the highest corre-
lation occurring between normal work and general
activity.
The PCA with varimax rotation extracted principal
components with a minimum Eigenvalue of 0.75 that
each explained more than 10% of the total variance.
Two components or symptom clusters were extracted
TABLE I Patient characteristics
               Characteristic Value
Patients (n)5 2
Sex [n (%)]
Male 29 (55.8)
Female 23 (44.2)
Age at radiation (years)
Mean ± SD 66.9±11.6
Median (range) 68.5 (39–87)
Karnofsky performance status
Mean ± SD 70.2±12.8
Median (range) 70 (40–90)
Total morphine equivalent (mg)
Mean ± SD 77.6±163
Median (range) 10 (0–880)
Primary cancer sites [n (%)]
Prostate 16 (30.8)
Breast 15 (28.9)
Lung 10 (19.2)
Bladder 4 (7.7)
Pancreas/gastric 3 (5.8)
Others 4 (7.7)
Sites of radiotherapy [n (%)]
Spine 22 (42.3)
Hips 9 (17.3)
Pelvis 7 (13.5)
Shoulders 5 (9.6)
Rib or ribs 4 (7.7)
Extremities 2 (3.8)
Other 3 (5.8)
Radiation dose [n (%)]
800 cGy/1 fraction 40 (76.9)
2000 cGy/5 fractions 11 (21.2)
3000 cGy/10 fractions 1 (1.9)
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from the questionnaire completed before RT, account-
ing for 77% of the total variance.
Cluster 1 included walking ability, general activ-
ity, normal work, and worst pain; it accounted for 67%
of the total variance. Cluster 2 included relations with
others, enjoyment of life, mood, and sleep; it accounted
for 10% of the total variance. Using the Cronbach al-
pha, the internal reliabilities of the two clusters were
high at 0.85 in cluster 2 and 0.92 in cluster 1, demon-
strating good internal consistency (Table V). The final
communalities showed that all the variables were well
accounted for by the two clusters, with final communality
estimates ranging from 0.57 for sleep to 0.93 for gen-
eral activity. Figure 1 shows a biplot for the two princi-
pal components, cluster 1 and cluster 2, depicting a
two-dimensional model. The two clusters are distinct,
being that they have different orientations. The arrows
of longer length and closer proximity suggest a higher
correlation between symptoms.
Because of attrition, follow-up response rates at
weeks 4, 8, and 12 were respectively 41.2%, 35.0%,
and 23.8% of the 52 patients. Using a general linear
mixed model, all worst pain and functional interfer-
ence scores significantly decreased over time (p <
0.0001), except for mood (p = 0.0002) and relations
with others (p = 0.0047, Table VI). However, total oral
morphine equivalent dose did not display a significant
change from baseline to week 12 (p = 0.8091, Table VI).
The percentages of patients who responded to RT
throughout the follow-up assessments were 60.1% at
week 4, 67.9% at week 8, and 73.7% at week 12. Ta-
ble VII sets out the number of patients at each time
point and the proportion that had a CR or PR to RT.
Because of the small sample size in the responder
and non-responder groups alike, we decided not to run
the PCA to extract symptom clusters. Any symptom
clusters extracted would not be reliable from a statisti-
cal viewpoint. Table VIII summarizes the symptom
cluster dynamics throughout the duration of the study.
In keeping with the criteria of extracting symptom clus-
ters with a minimum Eigenvalue of 0.75 and a mini-
mum proportion of variance of 10%, 2 clusters could
be extracted at baseline, at week 4, and at week 8.
However, these clusters did not remain consistent over
time; they varied at each time point. The functional
interference items that clustered consistently were
walking ability and general activity in cluster 1 and
relations with others and mood in cluster 2. The pair of
items in cluster 2 clustered together with those found
in cluster 1 after the initiation of RT in weeks 4 and 8.
At week 12, no symptom clusters that met the symp-
tom cluster criteria could be identified.
4. DISCUSSION
Our findings on clusters match the two factors extracted
in a Norwegian validation study of the BPI 15. Klepstad
and colleagues performed a principal factor analysis
with direct oblimin solution on a sample of 300 hospi-
talized cancer patients [55% men; median age: 63 years;
median KPS: 70 (range: 10–90)] 15. The most common
primary cancer sites were breast (20%), prostate (20%),
and lung (18%). Confirmed metastatic disease was
diagnosed in 235 patients. Klepstad et al. were able to
extract 2 factors: interference with physical function
(general activity, walking ability, and normal work),
and interference with psychological function (mood,
TABLE II Prevalence, sex difference, and median severity of worst pain and 7 functional interference items
      Symptom Functional prevalence Functional severity a
Total Overall Men Women χ2 Median
(n)[ n (%)] [n (%)] [n (%)] p Value b (range)
Worst pain 52 52 (100) 29 (100) 23 (100) 0.999 7 (1–10)
General activity 51 45 (88.2) 24 (85.7) 21 (91.3) 0.523 7 (2–10)
Enjoyment of life 50 44 (88.0) 25 (92.6) 19 (82.6) 0.279 7 (1–10)
Normal work 42 36 (85.7) 18 (85.7) 18 (85.7) 0.999 8 (2–10)
Walking ability 50 40 (80.0) 21 (77.8) 19 (82.6) 0.670 7 (2–10)
Mood 51 40 (78.4) 22 (78.6) 18 (78.3) 0.979 7 (1–10)
Sleep 51 40 (78.4) 20 (71.4) 20 (87.0) 0.180 6 (1–10)
Relations with others 50 31 (62.0) 13 (48.2) 18 (78.3) 0.029 6 (1–10)
a Functional severity in patients who scored greater than zero. 1 = minimum functional severity; 10 = worst possible functional severity.
b Sex difference as compared by chi-square test. “Total” is all patients who scored the item. “Overall” is all patients who scored the item
as greater than 0.
TABLE IIIWorst pain scores and functional interference items at base-
line (scale: 0–10)
      Symptom Patients Mean Median (range)
(n) ± SD
Worst pain 52 6.50±2.57 7 (1–10)
Normal work 42 6.24±3.46 7 (0–10)
General activity 51 5.90±3.20 6 (0–10)
Enjoyment of life 50 5.74±2.96 6 (0–10)
Walking ability 50 5.62±3.58 6 (0–10)
Mood 51 4.92±3.58 5 (0–10)
Sleep 51 4.90±3.61 5 (0–10)
Relations with others 50 3.60±3.48 3.5 (0–10)
SD = standard deviation.HADI et al.
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relations with others, sleep, and enjoyment of life) 15.
A third factor of pain severity was extracted in the
Norwegian study, which included worst, least, aver-
age, and current pain. However, only worst pain was
included in our study’s analysis. Consequently, worst
pain compounded the activity-related interference found
in our initial symptom cluster research in cancer pa-
tients with metastatic bone pain 11.
The findings in the present validation study differ
slightly from our initial symptom cluster research 11.
We extracted 2 symptom clusters before RT start, call-
ing cluster 1 “activity-related interference” and clus-
ter 2 “psychology-related interference.” These clusters
were reproducible at baseline in the current validation
study; however, in the previous study, enjoyment of life
was more highly correlated with the activity-related
interference items and compounded cluster 1 (activ-
ity-related interference) 11.
The initial findings in our previous study showed
that the statistical analysis failed to extract any symp-
tom clusters in the responder group after initiation of
RT 11. The symptom clusters had dispersed at weeks 4,
8, and 12, and no cluster could be extracted with fur-
ther statistical analysis (that is, PCA). The disintegra-
tion of the symptom clusters was attributed to the
alleviation of symptomatic bone pain, which thus had
a direct influence on the functional interference in all
7 items. The dynamics of the symptom clusters in the
responders showed that all items were affected, thus
further supporting the validity of the BPI 5.
The current validation study was able to extract 2
symptom clusters at weeks 4 and 8, and yet it failed to
extract any symptom clusters in week 12 of the fol-
low-up assessments. Although 2 symptom clusters were
observed, these clusters varied at each time point. The
items rearranged themselves to cluster with different
items in weeks 4 and 8.
Among the 8 items, walking ability and general
activity consistently remained together in cluster 1 (ac-
tivity-related interference). The consistency for this pair
of items is evidence of a common underlying construct,
which supports the theory developed by Kim et al. in
TABLE V Factor loadings and final communality from the principal
component analysis
                  Component a Final
1 2 communality
Walking ability 0.86 0.25 0.81
General activity 0.86 0.44 0.93
Normal work 0.84 0.36 0.84
Worst pain 0.64 0.59 0.75
Relations with others 0.21 0.82 0.73
Enjoyment of life 0.32 0.80 0.75
Mood 0.48 0.76 0.80
Sleep 0.39 0.65 0.57
Variance (%) 67 10
Cronbach alpha 0.92 0.85
a Boldface indicates a relationship between the functional
interference items in each component.
TABLE IV Spearman correlation among worst pain and functional interference items at baseline
           Items Worst General Mood Walking Normal Relations Sleep Enjoyment
pain activity ability work with others of life
Worst pain 1
General activity 0.65 1
Mood 0.66 0.77 1
Walking ability 0.56 0.80 0.60 1
Normal work 0.61 0.88 0.67 0.72 1
Relations with others 0.58 0.62 0.70 0.58 0.48 1
Sleep 0.45 0.48 0.57 0.38 0.57 0.41 1
Enjoyment of life 0.59 0.59 0.62 0.44 0.53 0.58 0.55 1
a p Value of Spearman correlation is highly significant (<0.0001) between items, except for sleep with worst pain (p = 0.0008), with
general activity (p = 0.0004), with walking ability (p = 0.0068), and with relations with others (p = 0.0029); enjoyment of life with
walking ability (p = 0.0014) and with normal work (p = 0.0003); and relations with others with normal work (p = 0.0015).
FIGURE 1   Biplot between components 1 and 2.VALIDATION OF SYMPTOM CLUSTERS
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2005 10. (Walking ability and general activity both in-
volve considerable physical activity of the lower limbs.)
On the other hand, relations with others and mood con-
sistently remained together, yet transferred from clus-
ter 2 (psychology-related interference) at baseline to
cluster 1 (activity-related interference) in weeks 4 and
8. The influence of pain on psychological symptoms
may be related to a combination of physical suffering
and a patient’s interpretation of pain in the context of
malignant disease.
At baseline, the 2 symptom clusters of activity-
related and psychology-related interference in the
present study differ slightly from those seen in the pre-
vious symptom cluster study 11. In the present research,
enjoyment of life had a stronger correlation with psy-
chology-related interference items than with activity-
related interference items (as in the past). We also
observed that “worst pain” had a higher correlation with
walking ability and general activity in cluster 1 and
therefore remained with these items at week 4. Inter-
estingly, “worst pain” clustered out of cluster 1 (activ-
ity-related interference) at week 4 and showed a stronger
correlation with interference with sleep in cluster 2 at
week 8 (Table VIII). We are unable to explain why a
patient’s worst pain would cluster with a subdued or
inactive state of sleeping than with a state that requires
TABLE VI  Distress scores of worst pain and functional interference items of all patients (Pts) over time a
        Item Baseline Week 4 Week 8 Week 12
Pts Mean ± SD Pts Mean ± SD Pts Mean ± SD Pts Mean ± SD
(n) (median) (n) (median) (n) (median) (n) (median)
Worst pain 52 6.5±2.6 (7) 33 3.7±3.2 (4) 28 2.6±3.3 (0.5) 19 3.1±3.3 (2)
General activity 51 5.9±3.2 (6) 31 3.7±3.8 (3) 27 2.6±3.4 (0) 19 2.7±3.2 (0)
Mood 51 4.9±3.6 (5) 32 3.4±3.8 (1.5) 28 2.0±3.2 (0) 19 2.2±3.0 (0)
Walking ability 50 5.6±3.6 (6) 32 3.5±3.5 (2.5) 28 2.6±3.5 (0) 19 2.8±3.7 (1)
Normal work 42 6.2±3.5 (7) 29 3.9±4.0 (3) 27 2.9±3.9 (0) 19 3.1±3.8 (2)
Relations with others 50 3.6±3.5 (3.5) 32 2.0±3.1 (0) 28 1.8±3.2 (0) 19 1.8±2.6 (0)
Sleep 51 4.9±3.6 (5) 31 2.8±3.1 (1) 27 1.8±3.0 (0) 19 1.8±2.9 (0)
Enjoyment of life 50 5.7±3.0 (6) 32 3.8±3.6 (3.5) 28 2.6±3.4 (0.5) 19 2.6±3.0 (2)
Total morphine equivalent 49 77.6±163.4 (10) 30 88.8±134.3 (3.5) 27 47.9±123.7 (0) 16 54.2±135.0 (0)
a Using a general linear mixed model, all pain and functional item scores decreased significantly over time (p < 0.0001), except for mood
(p = 0.0002) and relations with others (p = 0.0047). However, total oral morphine equivalent dose did not present a significant change
over time (p = 0.8091).
SD = standard deviation.
TABLE VII  Response rates
At 4 weeks At 8 weeks At 12 weeks
Patients (n)3 3 2 8 1 9
Complete response a [n (%)] 9 (27.3) 12 (42.9) 5 (26.3)
Partial response a [n (%)] 11 (33.3) 7 (25.0) 9 (47.4)
Responders [n (%)] 20 (60.1) 19 (67.9) 14 (73.7)
Non-responders [n (%)] 13 (39.4) 9 (32.1) 5 (26.3)
a Complete and partial responses were defined as set out by the
International Consensus of Bone Metastases Consensus
Working Party on palliative radiotherapy endpoints 14.
vigorous activity and stress on a patient’s body, such as
walking ability, general activity, and normal work.
Symptom clusters are a dynamic construct and
remain unpredictable across varied treatments, condi-
tions, and time periods. This symptom cluster phenom-
enon is not limited to the present research, but has also
been observed in earlier studies with symptom clus-
ters 16,17. Using the Edmonton Symptom Assessment
Scale on patients with bone 16 and brain metastases 17,
these two studies were able to extract symptom clus-
ters at baseline that rearranged at subsequent follow-
up weeks. Certain clusters changed after RT; others
remained stable. As a result, the findings in our present
study are not unexpected.
Kirkova and Walsh 18 refined the term “cluster sta-
bility” in an editorial published in Supportive Care in
Cancer. They defined cluster stability as a cluster com-
position across subjects and time. It can be conceptu-
alized as specific clusters that exist in a variety of
patient populations or those influenced by a common
intervention.
Symptom clusters are a dynamic construct and are
influenced by a specific symptom, its severity, treat-
ment, primary cancer site, stage of disease, and symp-
tom meaning 19–21. Bone metastases may have a
different meaning to the patient at different times dur-
ing the disease trajectory 18. This difference may ex-
plain the variation of symptom clusters in the present
study from baseline to weeks 4 and 8.
In comparing the present validation study to the
previous study conducted in 2007, we observed that
patients in the 2007 group had higher median “worst
pain” and functional interference (specifically, general
activity, walking ability, and enjoyment of life) scores.
They had less interference with relations with others.
Median scores for mood and sleep interference were
identical in both studies. The severity of an individu-
al’s bone pain symptoms may determine greater clus-
ter variability 18. Our study did not test for significance,HADI et al.
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but the differences in median score may account for
the cluster instability across the two studies.
4.1 Limitations
The differences between the two studies may be at-
tributable to the lesser number of patients in the present
validation study. A sample size of 52 patients is sig-
nificantly less than a population of 348 patients.
Comparisons between symptom cluster studies
remain difficult. The variations in cluster composition
are a direct result of the measurement instrument, the
study methodology, the statistical analysis, and the cut-
off points used to determine a symptom cluster 22–24.
Comparisons also remain an obstacle because no con-
sensus has yet been reached concerning the definition
of a symptom cluster and the clinical meaning of a
derived cluster.
The present validation study adds to the explora-
tion and further understanding of symptom cluster dy-
namics and the possible instability of symptom clusters
over time and over subjects. Symptom cluster research
is still being refined, but it may eventually facilitate
diagnosis and treatment follow-up, and may aid in pre-
dicting survival in clinical practice 18.
An additional validation study with a larger pa-
tient population is highly recommended. The sample
size in the present study was not large enough to pro-
duce reliable results. To rule out the phenomenon of
cluster instability, more studies must be conducted
using the same methodology of extracting symptom
clusters: for example, use of a standard instrument;
similar patient populations; identical definitions, cri-
teria, and cut-off points; and repeated assessments at
appropriate time intervals.
5. CONCLUSIONS
The refinement of definitions, development of criteria,
and determination of optimal statistical methods could
help to develop symptom cluster research standards and,
hopefully, to identify clinically important clusters 18.
Following verification of a symptom cluster, sub-
sequent research has to determine whether that cluster
occurs in other patient samples and whether it consti-
tutes a “symptom cluster diagnosis” 18. The same study
should be repeated in patient samples other than a bone
metastases group to see whether similar symptom clus-
ters can be extracted on the basis of cancer-related
pain in general.
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